FORMULATION AND EVALUATION OF MOXIFLOXACIN MICROSPHERES IMPLANT FOR INTRA-PERIODONTAL POCKETS

Periodontal disease is one of the most prevalent oral diseases is caused by the gram-negative bacterial infection of periodontal pocket identified by inflammation of subgingival plaque and degeneration of alveolar bones, teeth, dental cementum, and periodontal ligaments. 80% of American adult and more than 50% of the Indian community suffers from this chronic inflammatory infection depicting the severity of the Periodontitis disease. The available therapies are to minimize the bacterial infection and to regenerate the damage done by infection and inflammation. The therapies involve systemic therapy, conventional therapy, as well as local therapy. The localized drug delivery system using anti-bacterial drug Moxifloxacin is a fourth generation fluoroquinolone antibiotic drug used in periodontal infections. The present study aimed at designing and evaluating Eudragit-coated pectin microspheres for localized controlled release of drug to achieve a minimum inhibitory concentration in the periodontal pocket. The microspheres were prepared by emulsion dehydration technique using pectin as a polymer coated with Eudragit RS100. The formulation B2 were characterized by particle size, Scanning electron microscopy (SEM), swelling index (3.32%), drug entrapment efficiency (80.25%) and drug release (90.32%) in 6.8 phosphate buffer. The results indicated that the formulation of Eudragit coated Moxifloxacin pectin microspheres could be utilized to maintain the localized drug concentration for a longer period and increase patient compliance with lesser adverse effects.